Micro-Cap Brain Cancer Focused Plus Therapeutics Poised To Receive $3M From US Department of Defense

Plus Therapeutics Inc (NASDAQ:PSTV) has been selected for $3 million in funding recommendation by the Department of Defense (DoD) office of the Congressionally Directed Medical Research Programs. The

BenzingaApr 22 19:00

Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'

Plus Therapeutics Says 'Plus Now Has $23 Million in Active Awards Support for the Company's Targeted Radiotherapeutic Pipeline'

BenzingaApr 22 19:00

Press Release: Plus Therapeutics Receives $3 Million Award Recommendation From the United States Department of Defense

Plus Therapeutics Receives $3 Million Award Recommendation from the United States Department of Defense Plus now has $23 million in active awards support for the Company's targeted radiotherapeutic p

Dow JonesApr 22 19:00

Neuro-Oncologist Andrew Brenner, M.D., Ph.D. and Barbara Blouw, Ph.D. Join Plus' Management Team

The addition of both Dr. Brenner and Dr. Blouw substantially expands Plus internal expertise in key areas Dr. Brenner will maintain his academic commitments but will greatly contribute to Plus' scient

GlobeNewswireApr 9 19:00

Plus Therapeutics to Present at the National Comprehensive Cancer Network Annual Conference

AUSTIN, Texas, March 27, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced

GlobeNewswireMar 27 20:00

Buy Rating Affirmed for Plus Therapeutics Amidst Clinical Advancements and Industry Tailwinds

TipRanksMar 23 00:45